143 related articles for article (PubMed ID: 23482243)
1. A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect.
Thompson LF; Tsukamoto H; Chernogorova P; Zeiser R
Oncoimmunology; 2013 Jan; 2(1):e22107. PubMed ID: 23482243
[TBL] [Abstract][Full Text] [Related]
2. [Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy].
Tsukamoto H
Yakugaku Zasshi; 2014; 134(10):1021-7. PubMed ID: 25274211
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease.
Tsukamoto H; Chernogorova P; Ayata K; Gerlach UV; Rughani A; Ritchey JW; Ganesan J; Follo M; Zeiser R; Thompson LF; Idzko M
Blood; 2012 May; 119(19):4554-64. PubMed ID: 22262774
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.
Wang L; Fan J; Chen S; Zhang Y; Curiel TJ; Zhang B
PLoS One; 2013; 8(3):e58397. PubMed ID: 23520507
[TBL] [Abstract][Full Text] [Related]
8. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
[TBL] [Abstract][Full Text] [Related]
10. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
[TBL] [Abstract][Full Text] [Related]
12. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
13. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
Kobbe G; Schneider P; Aivado M; Zohren F; Schubert D; Fenk R; Neumann F; Kronenwett R; Pape H; Rong A; Royer-Pokora B; Hildebrandt B; Germing U; Gattermann N; Heyll A; Haas R
Exp Hematol; 2002 Nov; 30(11):1346-53. PubMed ID: 12423689
[TBL] [Abstract][Full Text] [Related]
14. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
Karimi MA; Bryson JL; Richman LP; Fesnak AD; Leichner TM; Satake A; Vonderheide RH; Raulet DH; Reshef R; Kambayashi T
Blood; 2015 Jun; 125(23):3655-63. PubMed ID: 25788701
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
16. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito M; Shizuru JA
Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Porter DL
Hematology Am Soc Hematol Educ Program; 2011; 2011():292-8. PubMed ID: 22160048
[TBL] [Abstract][Full Text] [Related]
20. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]